Literature DB >> 7532716

Immunohistological and functional analysis of adhesion molecule expression in the rheumatoid synovial lining layer. Implications for synovial lining cell destruction.

A C van Dinther-Janssen1, G Kraal, R M van Soesbergen, R J Scheper, C J Meijer.   

Abstract

OBJECTIVE: It has previously been shown that the adhesion of lymphocytes to microvascular endothelium mediates lymphocyte extravasation within inflamed synovium. After passing the endothelial barrier, binding of lymphocytes to matrix proteins and synovial lining cells may further lead to synovial membrane hyperplasia and subsequent cartilage destruction. Thus, we have explored the molecular basis of T cell-synovial lining cell interaction in the synovial membrane of patients with rheumatoid arthritis (RA).
METHODS: Using an immunohistochemical staining technique and an in vitro frozen section assay we studied the expression and the role of several adhesion molecules in T lymphocyte-synovial lining cell interaction in the inflamed synovial membrane.
RESULTS: In RA the macrophage-like (type A) synovial lining cells express high levels of intercellular adhesion molecule 1 [ICAM-1 (CD54)], whereas the fibroblast-like (type B) synovial lining cells predominantly express vascular cell adhesion molecule 1 (VCAM-1), in addition to moderate levels of ICAM-1. Both cell types express low levels of fibronectin. Unstimulated and anti-CD3 stimulated peripheral blood T cells bear the respective ligands lymphocyte function associated antigen 1 [LFA-1 (CD18/11a)], and very late antigen 4 and 5 [VLA-4 (CD29/49d) and VLA-5 (CD29/49e)]. T lymphocytes predominantly bound to type B synovial lining cells. Inhibition studies with monoclonal antibodies revealed that this binding involves the VLA-4/VCAM-1 and VLA-5/fibronectin (FN), but not the VLA-4/CS1 pathway. LFA-1 is also involved in this interaction via its ligand ICAM-1.
CONCLUSION: These results show that the molecular basis of T lymphocyte binding to rheumatoid synovial lining cells is different from that described for T lymphocyte binding to synovial membrane vascular endothelium which involves the VLA-4/VCAM-1 and VLA-4/CS-1 pathways, but not the LFA-1/ICAM-1 pathway.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7532716

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Vascular cell adhesion molecule-1 (VCAM-1) blockade in collagen-induced arthritis reduces joint involvement and alters B cell trafficking.

Authors:  R A Carter; I K Campbell; K L O'Donnel; I P Wicks
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

2.  Immunocytochemical identification of metallothionein-positive cells in rheumatoid synovium and analysis of their cell lineage.

Authors:  C Winters; B Jasani; S Marchant; A J Morgan
Journal:  Histochem J       Date:  1997-04

3.  TGFbeta1 regulates gene expression of its own converting enzyme furin.

Authors:  F Blanchette; R Day; W Dong; M H Laprise; C M Dubois
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

4.  Expression of adhesion molecules in synovia of patients with treatment-resistant lyme arthritis.

Authors:  E Akin; J Aversa; A C Steere
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

5.  Substance P enhances cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) expression on cultured rheumatoid fibroblast-like synoviocytes.

Authors:  N Lambert; P L Lescoulié; B Yassine-Diab; G Enault; B Mazières; C De Préval; A Cantagrel
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

6.  Junctional adhesion molecule C mediates leukocyte adhesion to rheumatoid arthritis synovium.

Authors:  Bradley J Rabquer; Angela Pakozdi; James E Michel; Bansari S Gujar; G Kenneth Haines; Beat A Imhof; Alisa E Koch
Journal:  Arthritis Rheum       Date:  2008-10

Review 7.  New therapeutic targets for rheumatoid arthritis.

Authors:  H J Dinant; B A Dijkmans
Journal:  Pharm World Sci       Date:  1999-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.